I’m currently working through some updates to the 2027 study materials! With any All Access pass, you’ll automatically get those updates when they become available in the coming weeks (November-December 2026 timeframe). I wanted to point out one update that may have slipped under your radar. The 2026 GOLD guidelines made an important change to COPD risk classification: just one moderate exacerbation in the previous year can place a patient in Group E.
Previously, Group E generally required two or more moderate exacerbations or at least one exacerbation requiring hospitalization. This change emphasizes that even a single outpatient exacerbation may signal increased risk for future events.
What Is a Moderate COPD Exacerbation?
A COPD exacerbation is an acute worsening of symptoms, such as shortness of breath, cough, or sputum production. Under traditional treatment-based definitions, a moderate exacerbation generally requires treatment with systemic corticosteroids and/or antibiotics. For example, a patient who develops worsening wheezing and dyspnea requiring prednisone may qualify for category E, even without hospitalization. The 2026 GOLD report also incorporates clinical criteria to assess exacerbation severity rather than relying exclusively on treatment setting.
How Does This Change Pharmacotherapy?
For patients classified as Group E, GOLD generally recommends initial dual long-acting bronchodilator therapy with a LAMA/LABA combination. For example, a patient taking tiotropium alone who experiences one outpatient exacerbation treated with prednisone should have their maintenance regimen reassessed. Switching to LAMA/LABA therapy may improve bronchodilation and reduce future exacerbation risk.
Key Takeaway
Pharmacists should pay attention to outpatient COPD exacerbations, including episodes treated with prednisone or antibiotics. Under the 2026 GOLD approach, one moderate exacerbation can trigger Group E classification and prompt reassessment of maintenance inhaler therapy. Full guideline reference.
0 Comments